In the most recent session, Medtronic, Inc. (NYSE:MDT) shares have traded +0.19%. Following the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent review, the stock has been noted $-1.52 away from the 50-day moving average of $79.59 and $-5.14 away from the 200-day moving average of $83.21. From a different angle, the stock has been recently recorded -12.98% off of the 52-week high of 89.72 and +12.57% removed from the 52-week low of 69.35.
Currently, Medtronic plc. Ordinary Shares has a price to earnings ratio of 26.28. Analysts and investors may also opt to evaluate a company's PEG or price to earnings growth ratio. The PEG ratio represents the ratio of the price to earnings to the anticipated future growth rate of the company. If a company has a PEG Ratio below one, it may be viewed as undervalued. If a company has a PEG Ratio above one, it may show that the company is overvalued. A PEG Ratio near one may be viewed as fair value. The stock currently has a PEG Ratio of 2.58.
Price Target Update
Analysts polled by Thomson Reuters have set a consensus target price of $89.97 on shares. Target prices may vary from one analyst to another due to the various ways they may proceed to calculate future price targets. This is a near-term estimation for the next 12-18 months.
For the current quarter, analysts are expecting Hologic, Inc. (NASDAQ:HOLX) to report EPS of $N/A. This consensus estimate is provided by Zacks Research. After the period that ended on N/A, Hologic, Inc. (NASDAQ:HOLX) reported an EPS actual of $N/A. The difference between the actual and estimate resulted in a surprise factor of N/A%. The company is expected to release their next earnings report on or around N/A. Interested parties will be watching to see how company results compare to what the Street was projecting for the fiscal period.
Shares of Hologic, Inc. (NASDAQ:HOLX) have a current ABR or average broker rating of N/A. This consensus recommendation is also provided by Zacks Research. The recommendation falls on a scale between 1 and 5. A broker rating of 1 would translate into a Strong Buy. A rating of 5 would indicate a Strong Sell recommendation. This consensus broker rating may help shed some light on how the sell-side is currently viewing company stock.
Covering analysts often provide target price projections for company shares. The current Zacks consensus target price on shares of Hologic, Inc. (NASDAQ:HOLX) is $N/A. The top analyst target is $N/A, and the lowest target is $N/A on the stock. Because of the different techniques used to gauge a company target price, estimates may be quite different from one analyst to another.